Suven Life shares surge over 4% on patents for drug

Shares of biopharma firm Suven Life Sciences today climbed over 4 per cent as the company has been granted two patents from Canada and one patent from China for a drug used in the treatment of neurodegenerative diseases.
The stock ended 4.27 per cent up at Rs 241.80 on the BSE. Intra-day, it surged 5.64 per cent to Rs 245.
At NSE, shares of the company were up 4.1 per cent to end at Rs 242.35.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
In a BSE filing, the company said it has been granted "two product patents from Canada and one product patent from China corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases."

These patents are valid through 2029 and 2030, the company added.
With this development, Suven Life Sciences' total count of patents stands at 20 from Canada and 18 from China.